Last updated: August 16, 2026
Ethyol is the branded injectable form of amifostine, a cytoprotective agent used mainly to reduce cisplatin-related nephrotoxicity and radiation-induced xerostomia. Its commercial profile is that of a mature, niche oncology-supportive product: core patent protection has expired, generic amifostine is available or commercially substitutable in the U.S., and demand is tied to a limited number of hospital-based treatment protocols. The product’s value depends more on supply reliability, contracting, clinical familiarity, and manufacturing economics than on exclusivity.
Standalone Ethyol revenue is not consistently disclosed in public company filings. Cumberland Pharmaceuticals, the current U.S. commercial partner, reports product-level and portfolio-level financial information inconsistently across reporting periods. Public filings do not support a reliable historical revenue series for Ethyol alone.
What is Ethyol and how is amifostine used?
Ethyol contains amifostine, a thiol prodrug that is converted to the active metabolite WR-1065. The active metabolite scavenges free radicals and provides preferential protection to certain normal tissues because of differences in vascular delivery and enzymatic activation.
The FDA-approved indications are:
| Indication |
Clinical purpose |
Administration context |
| Cisplatin chemotherapy |
Reduces cumulative renal toxicity in patients with advanced ovarian cancer receiving cisplatin-based therapy |
Intravenous infusion before chemotherapy |
| Head and neck radiotherapy |
Reduces moderate-to-severe xerostomia in patients receiving radiation therapy under standard fractionation |
Intravenous administration before radiation |
The FDA label does not establish amifostine as a broad protective agent for all chemotherapy regimens or radiation schedules. Its use is protocol-dependent, and the product carries clinically important administration requirements, including hydration, blood-pressure monitoring, and management of nausea and vomiting [1].
Ethyol is not an oral product, a biologic, or a specialty-delivery platform. Its commercial form is a sterile injectable product supplied in vials, which limits retail distribution and places purchasing decisions with hospitals, oncology centers, group purchasing organizations, and specialty distributors.
When did Ethyol lose exclusivity?
Ethyol lost meaningful U.S. market exclusivity after expiration of the patents associated with the original amifostine product and the introduction of generic amifostine injection. The product does not have a current small-molecule exclusivity position comparable to a newly approved oncology drug.
Ethyol exclusivity timeline
| Event |
Approximate timing |
Commercial consequence |
| FDA approval of Ethyol |
1996 |
Established the branded U.S. product |
| Initial patent-protected period |
Late 1990s to mid-2000s |
Supported branded pricing and market development |
| Patent expiry and generic entry risk |
Mid-2000s onward |
Reduced barriers to substitution |
| Commercial rights transition from MedImmune/AstraZeneca to Cumberland |
2010s |
Shifted the product to a focused mature-product portfolio |
| Current status |
2020s |
Mature branded injectable with limited differentiation |
The precise patent term depended on the relevant patent family, filing date, patent-term adjustment, and any regulatory extensions. The market outcome is clear: Ethyol is no longer protected by an effective composition-of-matter monopoly.
What patents protect Ethyol today?
No active patent estate appears to provide Ethyol with a meaningful current U.S. exclusivity barrier. Amifostine is an older small molecule, and the core product patents have expired or no longer prevent generic competition.
The relevant protection historically covered:
- Amifostine and related thiophosphate compounds.
- Pharmaceutical compositions containing amifostine.
- Use of amifostine to reduce toxicity associated with cytotoxic therapy.
- Injectable formulations and preparation methods.
The commercial importance of those patents has declined because:
- The active ingredient is long established.
- The FDA-approved indications are narrow and clinically familiar.
- Generic injectable products can compete without reproducing every branded commercial attribute.
- Hospital buyers generally evaluate injectable supportive-care products on price, supply, regulatory status, and contract terms.
Are formulation patents still important for Ethyol?
Formulation and manufacturing patents could affect a particular generic presentation, but they do not appear to create a durable market-wide barrier around Ethyol. The principal competitive issue is the ability to manufacture a stable sterile injectable product at commercially viable scale.
For amifostine, manufacturing barriers are more relevant than patent barriers. Key technical requirements include:
- Sterile manufacturing.
- Control of degradation and oxidation.
- Validated vial filling and packaging.
- Stability testing.
- Consistent reconstitution and infusion performance.
- Compliance with current good manufacturing practice requirements.
These requirements can restrict the number of reliable suppliers even when several legal competitors exist. That distinction matters in mature injectable markets: nominal generic availability does not always translate into continuous supply or aggressive price erosion.
What is the Orange Book status of Ethyol?
Ethyol is associated with FDA-approved amifostine labeling under NDA 020221. Its current commercial position should be evaluated through the FDA Orange Book for listed patents, exclusivity, reference-product status, and approved abbreviated applications [2].
The practical Orange Book assessment is:
| Category |
Ethyol position |
| Reference listed drug |
Ethyol/amifostine injection under the original NDA |
| Active ingredient exclusivity |
Expired |
| Current new-drug exclusivity |
None expected |
| Patent-based monopoly |
No meaningful current barrier apparent |
| Generic pathway |
ANDA-based competition is legally available |
| Biosimilar pathway |
Not applicable |
Orange Book status does not eliminate commercial barriers created by manufacturing complexity, shortages, hospital contracts, or limited supplier participation. It indicates the legal pathway for generic competition, not the guaranteed timing or scale of generic supply.
Which companies compete with Ethyol?
Ethyol competes across two levels: direct amifostine products and indirect alternatives that reduce reliance on amifostine.
Direct competitors
The direct competitive set includes:
- Generic amifostine injection manufacturers.
- Authorized distributors supplying equivalent injectable presentations.
- Hospital or health-system purchasing channels that substitute approved generic products for the branded product.
The exact active supplier list can change because injectable manufacturers enter and exit the market based on demand, manufacturing capacity, inspection outcomes, and pricing.
Indirect competitors
Indirect competition is more important than it may appear. Hospitals and oncologists can reduce demand for amifostine by using:
- Less nephrotoxic chemotherapy regimens.
- Alternative platinum dosing strategies.
- Aggressive hydration protocols.
- Modern radiation planning and intensity-modulated radiation therapy.
- Saliva-preserving treatment strategies.
- Different supportive-care protocols.
- Treatment regimens that avoid cisplatin where clinically appropriate.
The competitive market is therefore broader than “Ethyol versus generic amifostine.” It includes therapeutic substitution and changes in oncology practice.
How large is the Ethyol market?
Ethyol addresses a narrow hospital market rather than a large chronic-care category. Demand is constrained by:
- The declining use of amifostine in routine oncology practice.
- The availability of other renal-protection and hydration approaches.
- Selective use in radiation-associated xerostomia prevention.
- Intravenous administration requirements.
- Adverse events, particularly hypotension and nausea.
- Limited use outside the labeled settings.
No reliable public source establishes a current global Ethyol market size or a verified standalone revenue figure. Cumberland’s public financial disclosures should be used to track the broader portfolio and any product-specific commentary, but they do not provide a consistently reported, audited Ethyol revenue history [3].
What drives Ethyol demand?
Demand is determined by five variables:
- Cisplatin utilization in ovarian and other cancer treatment settings.
- Adoption of nephrotoxicity-prevention protocols.
- Use of standard-fractionation head and neck radiotherapy.
- Hospital formulary and purchasing decisions.
- Availability and price of generic amifostine.
Ethyol has a relatively defensive demand profile because some use is protocol-driven, but the overall addressable market remains small. A single hospital formulary decision can affect local volume materially.
What is the financial trajectory for Ethyol?
Ethyol’s financial trajectory is consistent with a mature branded injectable:
- Early growth came from regulatory approval, oncology adoption, and expansion into radiation-related supportive care.
- The product later faced patent expiry, generic competition, and a narrower clinical role.
- Commercial rights moved to a smaller specialty-pharmaceutical platform.
- Current economics depend on maintaining price and supply rather than expanding patient volume rapidly.
The product’s revenue potential is limited by low treatment frequency relative to chronic medicines and by the fact that its indications represent supportive care rather than disease treatment. Margins can remain attractive if the brand preserves price, has reliable supply, and serves institutions that prefer a known source. Volume growth is more difficult.
Revenue exposure for the current commercial partner
For Cumberland, Ethyol is one component of a diversified portfolio that has included hospital and specialty products such as Caldolor, Kristalose, Acetadote, Totect, Vaprisol, and other acquired or licensed medicines. This reduces corporate dependence on Ethyol but also limits the company’s incentive to invest heavily in a product with a mature market and limited exclusivity.
The financial risks are:
| Risk |
Effect on revenue |
| Generic substitution |
Reduces branded unit volume and price |
| Hospital contracting |
Compresses net price |
| Supply interruption |
Can cause immediate volume loss and formulary displacement |
| Declining cisplatin use |
Lowers nephrotoxicity-prevention demand |
| Clinical protocol changes |
Reduces utilization |
| Manufacturing cost inflation |
Pressures gross margin |
| Distributor concentration |
Increases customer and inventory risk |
A product-specific valuation should not assign Ethyol revenue based on total Cumberland revenue. Ethyol’s standalone contribution is not sufficiently disclosed in public filings to support that approach.
What generic entry risks exist for Ethyol?
Generic entry risk is high from a legal perspective and moderate to high from a commercial perspective.
Legal risk
A generic manufacturer can generally pursue an ANDA for amifostine injection once applicable patents and regulatory exclusivities have expired. A Paragraph IV challenge would have been most relevant before expiration of any listed patents. In the current market, the principal issue is not whether a generic can challenge Ethyol, but whether a supplier can obtain approval, maintain manufacturing compliance, and sell profitably.
Commercial risk
Generic competition can affect Ethyol through:
- Lower hospital acquisition cost.
- Therapeutic interchangeability or formulary substitution.
- Reduced distributor stocking of the branded product.
- Tender-based purchasing.
- Contracting pressure from group purchasing organizations.
The branded product may retain demand where clinicians prefer established supply, where the hospital has a branded contract, or where a generic supplier has a shortage. Those advantages are commercial and operational, not patent-based.
What is the FDA regulatory status of Ethyol?
Ethyol is an FDA-approved prescription injectable. Its regulatory status is tied to the original amifostine NDA and approved labeling. The product is not a biologic, so biosimilar competition is irrelevant. The correct regulatory comparator is an ANDA-approved generic injectable.
The principal regulatory and clinical limitations are:
- Intravenous administration.
- Need for blood-pressure monitoring.
- Risk of hypotension.
- Nausea and vomiting.
- Need for hydration.
- Restrictions on patient positioning and monitoring during administration.
- Limited evidence outside the labeled uses.
These factors increase the operational burden on treatment centers. A competing product that is cheaper but requires the same administration process does not create a major workflow advantage. Conversely, a future product with an easier administration route could displace amifostine more effectively than another conventional generic vial.
What patent litigation or Paragraph IV litigation affects Ethyol?
No major current U.S. patent litigation appears to define the Ethyol market. The product’s central patent disputes were historically relevant during the protected period, but present-day market risk is driven by generic pricing, supply, and clinical substitution.
There is no biosimilar litigation pathway because amifostine is a small-molecule drug. Any future litigation would more likely involve:
- ANDA approval or manufacturing disputes.
- Product liability.
- Trade-secret or manufacturing-process issues.
- Distribution and contract disputes.
- Regulatory enforcement concerning sterile injectable production.
A current investment or licensing analysis should treat Ethyol as a post-patent product without a litigation-driven exclusivity catalyst.
How does Ethyol compare with alternative renal and radiation-supportive products?
| Factor |
Ethyol |
Generic amifostine |
Non-amifostine supportive care |
| Active ingredient |
Amifostine |
Amifostine |
Varies |
| Patent protection |
Expired |
None meaningful |
Product-dependent |
| Administration |
IV |
IV |
May include hydration, treatment modification, or other measures |
| Main value proposition |
Tissue protection in selected settings |
Lower-cost equivalent approach |
Avoids amifostine-specific adverse effects or logistics |
| Key limitation |
Hypotension, nausea, monitoring |
Same clinical burden |
May provide less direct cytoprotection |
| Biosimilar risk |
None |
None |
None unless biologic |
| Pricing power |
Limited |
Low |
Depends on alternative |
Ethyol’s strongest commercial position is not based on technological differentiation from generic amifostine. It depends on brand familiarity, supply continuity, and institutional preference.
What licensing deals affect Ethyol?
The key commercial transition was the movement of Ethyol from the original developer and large-pharmaceutical ownership structure into Cumberland Pharmaceuticals’ specialty portfolio. MedImmune acquired US Bioscience in 2005, bringing Ethyol into MedImmune’s assets. AstraZeneca later owned MedImmune. Cumberland subsequently acquired U.S. rights to Ethyol from AstraZeneca in the 2010s, according to Cumberland’s corporate disclosures and product materials [3,4].
This rights history is important because it explains the product’s current commercial model:
- Original development and commercialization by US Bioscience.
- Ownership transition through MedImmune and AstraZeneca.
- Later commercialization by a smaller specialty company.
- Focus on mature-product sales rather than new molecular innovation.
The deal structure and royalty economics should be reviewed in the relevant transaction filings before assigning value to Ethyol. Public disclosures do not support a precise current estimate of milestone, royalty, or transfer-pricing obligations without reviewing the underlying agreements.
What geographic coverage does Ethyol have?
Ethyol’s most relevant commercial market is the United States. Rights and regulatory status differ by country, and international amifostine products may be marketed under different brand names, local registrations, or generic labels.
Geographic risks include:
- Country-specific patent and data-exclusivity rules.
- Different oncology treatment protocols.
- Local hospital procurement systems.
- Sterile injectable manufacturing capacity.
- National reimbursement policies.
- Regulatory variation for indications and labeling.
A global valuation should not extrapolate U.S. Ethyol performance directly to Europe, Asia, or emerging markets. In many countries, generic amifostine or locally registered formulations may have greater influence than the U.S. brand.
What is the outlook for Ethyol through the late 2020s?
The base-case outlook is stable to declining revenue with episodic upside from supply disruption or price increases. Large volume growth is unlikely without a new clinical indication, a new delivery system, or evidence that changes treatment guidelines.
The principal upside scenarios are:
- A shortage affecting generic amifostine supply.
- Increased cisplatin use in a high-volume oncology segment.
- Greater adoption for radiation-induced xerostomia prevention.
- Successful premium positioning based on reliable supply.
- Expansion into a new formulation or administration route.
The principal downside scenarios are:
- Additional generic suppliers entering the market.
- Hospital conversion to lower-cost alternatives.
- Reduced use of cisplatin.
- Expanded use of modern radiotherapy techniques that reduce xerostomia.
- Manufacturing or distribution interruption.
- Clinical concerns about hypotension, nausea, or monitoring burden.
Key Takeaways
- Ethyol is the branded injectable formulation of amifostine.
- Its FDA-approved uses are cisplatin nephrotoxicity reduction and prevention of radiation-induced xerostomia in selected patients.
- Core patent and regulatory exclusivity have expired.
- The product has no biosimilar risk because amifostine is a small molecule.
- Generic competition is legally available and is the principal pricing threat.
- Manufacturing reliability and sterile injectable capacity are more important than patent protection.
- Cumberland Pharmaceuticals is the relevant current U.S. commercial platform following the product’s transfer from AstraZeneca.
- Standalone Ethyol revenue is not consistently disclosed, preventing a reliable product-level financial time series from public filings.
- The market is mature, hospital-based, protocol-dependent, and likely stable to declining absent new clinical or formulation differentiation.
- Any valuation should model Ethyol as a post-exclusivity supportive-care product with supply and contracting sensitivity.
FAQs
Is Ethyol still commercially available in the United States?
Ethyol has been commercially marketed in the United States through Cumberland Pharmaceuticals, although availability can vary by distributor, hospital contract, and injectable-product supply conditions.
Is amifostine interchangeable with Ethyol?
An FDA-approved generic amifostine product may be substitutable under applicable pharmacy and institutional rules. Actual substitution depends on the approved product, state law, hospital formulary policy, and procurement contract.
Does Ethyol have pediatric exclusivity?
There is no current pediatric exclusivity position that materially affects the commercial market for Ethyol.
Can Ethyol be used to prevent toxicity from all platinum chemotherapy?
No. FDA-approved labeling is narrower. Use in other platinum regimens or treatment settings requires separate clinical and regulatory support.
What would most improve Ethyol’s commercial value?
A differentiated formulation that reduces infusion burden or adverse effects would have the greatest potential commercial impact. New clinical evidence supporting broader use could also increase demand, but would not by itself restore the product’s expired patent exclusivity.
References
- U.S. Food and Drug Administration. (2023). Ethyol (amifostine) injection prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Cumberland Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Cumberland Pharmaceuticals, Inc. (n.d.). Ethyol product information and corporate portfolio materials.
- National Cancer Institute. (n.d.). Amifostine. NCI Drug Dictionary.
